As of Friday close, Emergent BioSolutions Inc.’s (NYSE:EBS) stock was down -$1.53, moving down -15.85 percent to $8.12. The average number of shares traded per day over the past five days has been 1,530,060 shares. 2 times new highs have been achieved over the past 5 days, with a -$1.57 fall in that time frame. In the last twenty days, the average volume was 1,616,185, while in the previous 50 days, it was 1,169,274.
Since last month, EBS stock retreated -45.58%. Shares of the company fell to $8.11 on 03/17/23, the lowest level in the past month. A 52-week high of $45.14 was reached on 02/21/23 after having rallying from a 52-week low of $9.17. Since the beginning of this year, EBS’s stock price has dropped by -31.24% or -$3.69, and marked a new high 11 times. However, the stock has declined by -82.01% since its 52-week high.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
EBS stock investors should be aware that Emergent BioSolutions Inc. (EBS) stock had its last reported insider trading activity 113 days ago on Nov 25. Richard Ronald, the Director of the company, disposed of 1,912 shares for $11.94 on Nov 25. It resulted in a $22,829 divestment by the insider. Zoon Kathryn C sold 1,173 shares at an average price of $31.52 on Jun 09. The insider now owns 19,654 shares following the transaction. On May 24, Director Zoon Kathryn C sold 1,996 shares at $35.53 apiece. The transaction was valued at $70,918.
The stock’s beta is 0.98. Besides these, the trailing price-to-sales (P/S) ratio of 0.38, the price-to-book (PB) ratio of 0.29.
In the three months ended December 30, Emergent BioSolutions Inc.’s quick ratio stood at 0.70, while its current ratio was 1.00, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending December 30 was 0.32, and the total debt-to-equity ratio was 1.02. On the profitability front, the trailing twelve-month gross margin is 38.10% percent. In the year ended December 30, operating margins totaled -15.40%. Based on annual data, EBS earned $427.2 million in gross profit and brought in $1.12 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -6.30%. Return on equity (ROE) for the past 12 months was -15.10%.
In Emergent BioSolutions Inc.’s quarter-end financial report for December 30, it reported total debt of $448.5 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. EBS’s revenue fell -118.69% during the quarter, while net income inched up to $330.7 million. While analysts expected Emergent BioSolutions Inc. to report $0.04 quarterly earnings, the actual figure was -$0.31 per share, beating the consensus estimate by -875.00%. The liabilities of Emergent BioSolutions Inc. were 1.78 billion at the end of its most recent quarter ended December 30, and its total debt was $1.43 billion.
This quick technical analysis looks at Emergent BioSolutions Inc.’s (EBS) price momentum. With a historical volatility rate of 78.72%, the RSI 9-day stood at 15.30% on 17 March.
With respect to its five-day moving average, the current Emergent BioSolutions Inc. price is down by -16.20% percent or -$1.57. At present, EBS shares trade -45.06% below its 20-day simple moving average and -56.48% percent below its 100-day simple moving average. However, the stock is currently trading approximately -34.99% below its SMA50 and -75.36% below its SMA200.
Stochastic coefficient K was 6.19% and Stochastic coefficient D was 6.75%, while ATR was 0.80. Given the Stochastic reading of 0.18% for the 14-day period, the RSI (14) reading has been calculated as 23.44%. As of today, the MACD Oscillator reading stands at -0.59, while the 14-day reading stands at -1.32.
Emergent BioSolutions Inc. downgraded its rating on Emergent BioSolutions Inc. (NYSE: EBS) to an Underweight in a note to investors on March 17, 2023. The analysts firm previously had a Neutral rating on the stock.Emergent BioSolutions Inc. (EBS) has been rated Hold by analysts. According to 1 brokerage firm, EBS is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Emergent BioSolutions Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $21.00, the current consensus forecast for the stock is $9.00 – $55.00. Based on these forecasts, analysts predict Emergent BioSolutions Inc. (EBS) will achieve an average price target of $25.00.